Back to results
US 12,534,541 B2Granted
Anti-PTK7 antibody and uses thereof
AssigneeMabcare Therapeutics
InventorTao Meng
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to anti-PTK7 antibodies or antigen-binding fragments thereof, nucleic acid molecules encoding the same, and use thereof in preparation of antibody-drug conjugates, and further relates to antibody-drug conjugates containing the antibodies or antigen-binding fragments thereof and preparation method and use thereof.
Claims41
A compound of formula (I) or a pharmaceutically acceptable salt thereof,
- wherein:
- Ab is an anti-PTK7 antibody or antigen-binding fragment thereof, comprising:
- (a) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1), a heavy chain complementarity determining region 2 (HC CDR2), and a heavy chain complementarity determining region 3 (HC CDR3), wherein:
- HC CDR1 is SEQ ID NO:
- 1, HC CDR2 is SEQ ID NO:
- 2, and HC CDR3 is SEQ ID NO:
- 3;
- or
- HC CDR1 is SEQ ID NO:
- 7, HC CDR2 is SEQ ID NO:
- 8, and HC CDR3 is SEQ ID NO:3;
- or
- HC CDR1 is SEQ ID NO:
- 13, HC CDR2 is SEQ ID NO:
- 14, and HC CDR3 is SEQ ID NO:
- 15;
- and
- (b) a light chain variable region (VL) comprising a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and a light chain complementarity determining region 3 (LC CDR3), wherein:
- LC CDR1 is SEQ ID NO:
- 4, LC CDR2 is SEQ ID NO:
- 5, and LC CDR3 is SEQ ID NO:
- 6;
- or
- LC CDR1 is SEQ ID NO:
- 10, LC CDR2 is SEQ ID NO:
- 11, and LC CDR3 is SEQ ID NO:
- 12;
- or
- LC CDR1 is SEQ ID NO:
- 16, LC CDR2 is SGS, and LC CDR3 is SEQ ID NO:
- 18;
- T is a drug unit or a diagnostic reagent unit;
- m is a number between 1 and 8;
- Q1 is selected from:
- substituted
- substituted,
- substituted,
- and substituted
- L1 is -L1a-C(═O)-, wherein L1a is selected from alkylene, polyethylene glycol group, alkenylene, alkynylene, alicylidene, aliphatic heterocyclylene, arylene, heteroarylene, substituted alkylene, substituted polyethylene glycol group, substituted alkenylene, substituted alkynylene, substituted alicylidene, substituted aliphatic heterocyclylene, substituted arylene, and substituted heteroarylene;
- L2 is a polypeptide residue or a substituted polypeptide residue;
- and
- L3 is
- or substituted
40 more elements
An anti-PTK7 antibody or an antigen-binding fragment thereof, comprising:
- (a) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1), a heavy chain complementarity determining region 2 (HC CDR2), and a heavy chain complementarity determining region 3 (HC CDR3), wherein:
- HC CDR1 is SEQ ID NO:
- 1, HC CDR2 is SEQ ID NO:
- 2, and HC CDR3 is SEQ ID NO:
- 3;
- or
- HC CDR1 is SEQ ID NO:
- 7, HC CDR2 is SEQ ID NO:
- 8, and HC CDR3 is SEQ ID NO:3;
- or
- HC CDR1 is SEQ ID NO:
- 13, HC CDR2 is SEQ ID NO:
- 14, and HC CDR3 is SEQ ID NO:
- 15;
- and
- (b) a light chain variable region (VL) comprising a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and a light chain complementarity determining region 3 (LC CDR3), wherein:
- LC CDR1 is SEQ ID NO:
- 4, LC CDR2 is SEQ ID NO:
- 5, and LC CDR3 is SEQ ID NO:
- 6;
- or
- LC CDR1 is SEQ ID NO:
- 10, LC CDR2 is SEQ ID NO:
- 11, and LC CDR3 is SEQ ID NO:
- 12;
- or
- LC CDR1 is SEQ ID NO:
- 16, LC CDR2 is SGS, and LC CDR3 is SEQ ID NO:
- 18.
26 more elements
A method of preparing a compound or a pharmaceutically acceptable salt thereof, comprising:
- contacting Ab with a compound selected from formula L-D-1 to L-D-11:
- to obtain a compound of formula (I):
- wherein:
- Ab is an anti-PTK7 antibody or antigen-binding fragment thereof comprising:
- (a) a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1), a heavy chain complementarity determining region 2 (HC CDR2), and a heavy chain complementarity determining region 3 (HC CDR3), wherein:
- HC CDR1 is SEQ ID NO:
- 1, HC CDR2 is SEQ ID NO:
- 2, and HC CDR3 is SEQ ID NO:
- 3;
- or
- HC CDR1 is SEQ ID NO:
- 7, HC CDR2 is SEQ ID NO:
- 8, and HC CDR3 is SEQ ID NO:3;
- or
- HC CDR1 is SEQ ID NO:
- 13, HC CDR2 is SEQ ID NO:
- 14, and HC CDR3 is SEQ ID NO:
- 15;
- and
- (b) a light chain variable region (VL) comprising a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and a light chain complementarity determining region 3 (LC CDR3), wherein:
- LC CDR1 is SEQ ID NO:
- 4, LC CDR2 is SEQ ID NO:
- 5, and LC CDR3 is SEQ ID NO:
- 6;
- or
- LC CDR1 is SEQ ID NO:
- 10, LC CDR2 is SEQ ID NO:
- 11, and LC CDR3 is SEQ ID NO:
- 12;
- or
- LC CDR1 is SEQ ID NO:
- 16, LC CDR2 is SGS, and LC CDR3 is SEQ ID NO:
- 18.
30 more elements
Dependencies are inferred from the claim text.